The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Chitcholtan, Kenny ^a   Sykes, Peter H ^b   Evans, John J ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CHRISTCHURCH WOMEN S HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLINE; DOXORUBICIN; GLUCOSE; GLUCOSE TRANSPORTER 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN AKT1; PROTEIN AKT3; PROTEIN KINASE B; PROTEIN KINASE B BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; 2 (N (7 NITROBENZ 2 OXA 1,3 DIAZOL 4 YL)AMINO) 2 DEOXYGLUCOSE; 2-(N-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)AMINO)-2-DEOXYGLUCOSE; 4 CHLORO 7 NITROBENZOFURAZAN; ANTIOXIDANT; BETA1 INTEGRIN; DEOXYGLUCOSE; DRUG DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; SLC2A1 PROTEIN, HUMAN; SUPEROXIDE DISMUTASE; VASCULOTROPIN A;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG RESISTANCE; ENDOMETRIUM CANCER; ENZYME PHOSPHORYLATION; GLUCOSE METABOLISM; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MONOLAYER CULTURE; PROTEIN EXPRESSION; PROTEIN SECRETION; CELL SURVIVAL; CLASSIFICATION; DENSITOMETRY; ENDOMETRIUM TUMOR; ENZYMOLOGY; FEMALE; HUMAN; INTRACELLULAR SPACE; METABOLISM; METHODOLOGY; MULTICELLULAR SPHEROID; PATHOLOGY; PHOSPHORYLATION; SECRETION; TISSUE CULTURE TECHNIQUE; TUMOR CELL CULTURE;

4-CHLORO-7-NITROBENZOFURAZAN; ANTIGENS, CD29; ANTIOXIDANTS; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DENSITOMETRY; DEOXYGLUCOSE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; INTRACELLULAR SPACE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SPHEROIDS, CELLULAR; SUPEROXIDE DISMUTASE; TISSUE CULTURE TECHNIQUES; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84857763458     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-38     Document Type: Article

References (51)

1. Purdie DM, Green AC. Epidemiology of endometrial cancer. Best Pract Res Clin Obstet Gynaecol 2001, 15:341-354. 10.1053/beog.2000.0180, 11476557.
2. Parazzin F, Vecchia CL, Bocciolone L, Franceschi S. The Epidemiology of endometrial cancer. Gynecol Oncol 1991, 41:1-16. 10.1016/0090-8258(91)90246-2, 2026352.
3. Lindemann K, Eskild A, Vatten LJ, Bray F. Endometrial cancer incidence trends in Norway during 1953-2007 and predictions for 2008-2027. Int J Cancer 2010, 127:2661-2668. 10.1002/ijc.25267, 20162667.
4. Boruta DM, Gehrig PA, Groben PA, Bae-Jump V, Boggess JF, Fowler JWC, et al. Uterine serous and grade 3 endometrioid carcinomas. Is there a survival difference?. Cancer 2004, 101:2214-2221. 10.1002/cncr.20645, 15452833.
5. Huszar M, Pfeifer M, Schirmer U, Kiefel H, Konecny GE, Ben-Arie A, et al. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol 2010, 220:551-561. 10.1002/path.2673, 20077528.
6. Efferth T, Konkimalla VB, Wang Y, Sauerbrey A, Meinhardt S, Zintl F, et al. Prediction of broad spectrum resistance of tumors towards anticancer drugs. Clin Cancer Res 2008, 14:2405-2412. 10.1158/1078-0432.CCR-07-4525, 18413831.
7. Cella D, Huang H, Homesley HD, Montag A, Salani R, Geest KD, et al. Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: results from GOG 184. Gynecol Oncol 2010, 119:538-542. 10.1016/j.ygyno.2010.08.022, 20863554.
8. Smith JA, Brown J, Martin MC, Ramondetta LM, Wolf JK. An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines. Gynecol Oncol 2004, 92:314-319. 10.1016/j.ygyno.2003.09.037, 14751176.
9. Thigpen T, Vance R, Khansur T. The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Semin Oncol 1995, 22(Suppl 12):67-75.
10. Zietarska M, Maugard CM, Filali-Mouhim A, Alam-Fahmy M, Tonin PN, Provencher DM, et al. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol Carcinog 2007, 46:872-885. 10.1002/mc.20315, 17455221.
11. Green SK, Francia G, Isidoro C, Kerbel RS. Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. Mol Cancer Ther 2004, 3:149-159.
12. Casey RC, Burleson KM, Skubitz KM, Pambuccian SE, Oegema TR, Ruff LE, et al. β1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am J Pathol 2001, 159:2071-2080. 10.1016/S0002-9440(10)63058-1, 1850600, 11733357.
13. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006, 6:583-592. 10.1038/nrc1893, 16862189.
14. Timmins NE, Dietmair S, Nielsen LK. Hanging-drop multicellular spheroids as a model of tumour angiogenesis. Angiogenesis 2004, 7:97-103. 10.1007/s10456-004-8911-7, 15516830.
15. Wartenberg M, Hescheler J, Acker H, Diedershagen H, Sauer H. Doxorubicin distribution in multicellular prostate cancer spheroids evaluated by confocal laser scanning microscopy and the "optical probe technique". Cytometry 1998, 31:137-145. 10.1002/(SICI)1097-0320(19980201)31:2<137::AID-CYTO9>3.0.CO;2-J, 9482283.
16. Valcárcel M, Arteta B, Jaureguibeitia A, Lopategi A, Martínez I, Mendoza L, et al. Three-dimensional growth as multicellular spheroid activates the proangiogenic phenotype of colorectal carcinoma cells via LFA-1-dependent VEGF: implications on hepatic micrometastasis. J Transl Med 2008, 6:57. 10.1186/1479-5876-6-57, 2579286, 18844982.
17. Sutherland RM, Sordat B, Bamat J, Gabbert H, Bourrat B, Mueller-Klieser W. Oxygenationand differentiation in multicellular spheroids of human colon carcinoma. Cancer Res 1986, 46:5320-5329.
18. Kwon DS, Kwon CH, Kim JH, Woo JS, Jung JS, Kim YK. Signal transduction of MEK/ERK and PI3K/Akt activation by hypoxia/reoxygenation in renal epithelial cells. Eur J Cell Biol 2006, 85:1189-1199. 10.1016/j.ejcb.2006.06.001, 16860436.
19. L'Espérance S, Bachvarova M, Tetu B, Mes-Masson A, Bachvarov D. Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics 2008, 26:99.
20. Sodek KL, Ringuette MJ, Brown TJ. Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. Int J Cancer 2009, 124:2060-2070. 10.1002/ijc.24188, 19132753.
21. Ivascu A, Kubbies M. Rapid generation of single-tumor spheroids for high-throughput cell function and toxicity analysis. J Biomol Screen 2006, 11:922-932. 10.1177/1087057106292763, 16973921.
22. Lin R, Chou L, Michael CC, Chang H. Dynamic analysis of hepatoma spheroid formation: roles of E-cadherin and β1-integrin. Cell Tissue Res 2006, 324:411-422. 10.1007/s00441-005-0148-2, 16489443.
23. Nishimura M, Saito T, Yamasaki H, Kudo R. Suppression of gap junctional intercellular communication via 5' CpG island methylation in promoter region of E-cadherin gene in endometrial cancer cells. Carcinogenesis 2003, 24:1615-1623. 10.1093/carcin/bgg121, 12896902.
24. Castelbaum AJ, Ying L, Somkuti SG, Sun J, Ilesanmi AO, Lessey BA. Characterization of integrin expression in a well differentiated endometrial adenocarcinoma cell line (Ishikawa). J Clin Endocrinol Metab 1997, 82:136-142. 10.1210/jc.82.1.136, 8989247.
25. Park KR, Inoue T, Ueda M, Hirano T, Higuchi T, Konishi I, et al. Anti-CD9 monoclonal antibody-stimulated invasion of endometrial cancer cell lines in vitro: possible inhibitory effects of CD9 in endometrial cancer invasion. Mol Hum Reprod 2000, 6:719-725. 10.1093/molehr/6.8.719, 10908282.
26. Albitar L, Carter MB, Davies S, Leslie KK. Consequences of the loss of p53, RB1, and PTEN: relationship to gefitinib resistance in endometrial cancer. Gynecol Oncol 2007, 106:94-104. 10.1016/j.ygyno.2007.03.006, 17490733.
27. Rantanen V, Engblom P, Raitanen M, Hietanen S, Haarala M, Grénmanb S, et al. Mutations of TP53 do not correlate with the sensitivity to paclitaxel-a study using 27 gynaecological cancer cell lines. Eur J Cancer 2002, 38:1783-1791. 10.1016/S0959-8049(02)00119-3, 12175696.
28. Yaginuma Y, Westphal H. Analysis of the p53 gene in human uterine carcinoma cell lines. Cancer Res 1991, 51:6506-6509.
29. Kanayama S, Yamada Y, Kawaguchi R, Tsuji Y, Haruta S, Kobayashi H. Hepatocyte growth factor induces anoikis resistance by up-regulation of cyclooxygenase-2 expression in uterine endometrial cancer cells. Oncol Rep 2008, 19:117-122.
30. Gagnon V, Themsche CV, Turner S, Leblanc V, Asselin E. Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis 2008, 13:259-271. 10.1007/s10495-007-0165-6, 18071906.
31. Fayad W, Brnjic S, Berglind D, Blixt S, Shoshan MC, Berndtsson M, et al. Restriction of cisplatin induction of acute apoptosis to a subpopulation of cells in a three-dimensional carcinoma culture model. Int J Cancer 2009, 125:2450-2455. 10.1002/ijc.24627, 19670329.
32. Ferrante A, Rainaldi G, Indovina P, Indovina PL, Santini MT. Increased cell compaction can augment the resistance of HT-29 human colon adenocarcinoma spheroids to ionizing radiation. Int J Oncol 2006, 28:111-118.
33. Vassileva V, Allen CJ, Piquette-Miller M. Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer. Mol Cancer Ther 2008, 7:630-637. 10.1158/1535-7163.MCT-07-2117, 18347149.
34. Davis AJ, Chapman W, Hedley DW, Oza AM, Tannock IF. Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer: pilot study. Cytometry 2003, Part A 51A:1-6.
35. Polo ML, Arnoni MV, Riggio M, Wargon V, Lanari C, Novaro V. Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice. PLoS One 2010, 5:e10786. 10.1371/journal.pone.0010786, 2877092, 20520761.
36. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM. mTOR inhibition reverses Akt dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004, 10:594-601. 10.1038/nm1052, 15156201.
37. Medina RA, Meneses AM, Vera JC, Gúzman C, Nualart F, Rodriguez F, et al. Differential regulation of glucose transporter expression by estrogen and progesterone in Ishikawa endometrial cancer cells. J Endocrinol 2004, 182:467-478. 10.1677/joe.0.1820467, 15350188.
38. Chan MM, Soprano KJ, Weinstein K, Fong D. Epigallocatechin-3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility. J Cell Physiol 2006, 207:389-396. 10.1002/jcp.20569, 16402374.
39. Finn NA, Findley HW, Kemp ML. A switching mechanism in doxorubicin bioactivation can be exploited to control doxorubicin toxicity. PLoS Comput Biol 2011, 7:e1002151. 10.1371/journal.pcbi.1002151, 3174179, 21935349.
40. Grun B, Benjamin E, Sinclair J, Timms JF, Jacobs IJ, Gayther SA, et al. Three-dimensional in vitro cell biology models of ovarian and endometrial cancer. Cell Prolif 2009, 42:219-228. 10.1111/j.1365-2184.2008.00579.x, 19222485.
41. Lee SY, Jeong EK, Jeon HM, Kim CH, Kang HS. Implication of necrosis-linked p53 aggregation in acquired apoptotic resistance to 5-FU in MCF-7 multicellular tumour spheroids. Oncol Rep 2010, 24:73-79.
42. Khaitan D, Chandna S, Arya M, Dwarakanath B. Establishment and characterization of multicellular spheroids from a human glioma cell line; Implications for tumor therapy. J Transl Med 2006, 4:12. 10.1186/1479-5876-4-12, 1420330, 16509995.
43. Fischbach C, Chen R, Matsumoto T, Schmelzle T, Brugge JS, Polverini PJ, et al. Engineering tumors with 3D scaffolds. Nat Methods 2007, 4:855-860. 10.1038/nmeth1085, 17767164.
44. Hawinkelsa LJAC, Zuidwijka K, Verspageta HW, de Jonge-Mullera ESM, van Duijna W, Ferreirab V, et al. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur J Cancer 2008, 44:1904-1913. 10.1016/j.ejca.2008.06.031, 18691882.
45. St-Germain M, Gagnon V, Parent S, Asselin E. Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-kB/IkB pathway. Mol Cancer 2004, 3:1-11. 10.1186/1476-4598-3-1, 324565, 14723797.
46. Humtsoe JO, Kramer RH. Differential epidermal growth factor receptor signaling regulates anchorage-independent growth by modulation of the PI3K/AKT pathway. Oncogene 2010, 29:1214-1226. 10.1038/onc.2009.419, 2829113, 19935697.
47. Li X, Lu Y, Liang K, Liu B, Fan Z. Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells. Breast Cancer Res 2005, 7:R589-R597. 10.1186/bcr1259, 1242125, 16168102.
48. Barbone D, Yang T, Morgan JR, Gaudino G, Broaddus VC. Mammalian Target of Rapamycin Contributes to the Acquired Apoptotic Resistance of Human Mesothelioma Multicellular Spheroids. J Biol Chem 2008, 283:13021-13030. 10.1074/jbc.M709698200, 2442321, 18339627.
49. Gagnon V, Mathieu I, Sexton E, Leblanc K, Asselin E. AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol 2004, 94:785-795. 10.1016/j.ygyno.2004.06.023, 15350374.
50. Jack GD, Cabrera MC, Manning ML, Slaughter SM, Potts M, Helm RF. Activated stress response pathways within multicellular aggregates utilize an autocrine component. Cell Signal 2007, 19:772-781. 10.1016/j.cellsig.2006.10.005, 17127033.
51. Wada Y, Shimada K, Kimura T, Ushiyama S. Novel p38 MAP kinase inhibitor R-130823 suppresses IL-6, IL-8 and MMP-13 production in spheroid culture of human synovial sarcoma cell line SW 982. Immunol Lett 2005, 101:50-59. 10.1016/j.imlet.2005.04.010, 15888346.